Cargando…
Recombinant and Plasma-Purified Human C1 Inhibitor for the Treatment of Hereditary Angioedema
BACKGROUND: Agents for prophylaxis of hereditary angioedema (HAE) have been available in the United States for several decades, but their usefulness is limited by side effects and they cannot be used at all in some patients. No agents have been available in the United States to specifically treat ac...
Autor principal: | Frank, Michael M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666149/ https://www.ncbi.nlm.nih.gov/pubmed/23282867 http://dx.doi.org/10.1097/1939-4551-3-S3-S29 |
Ejemplares similares
-
The Pathophysiology of Hereditary Angioedema
por: Zuraw, Bruce L
Publicado: (2010) -
Hereditary Angioedema Therapy: Kallikrein Inhibition and Bradykinin
Receptor Antagonism
por: Riedl, Marc
Publicado: (2010) -
Introduction: New Perspectives in Hereditary Angioedema (HAE):
Molecular Mechanisms & Therapeutic Choices: A CME Symposium
Presented at the 2009 World Allergy Congress, Buenos Aires, Argentina,
December 9, 2009
por: Zuraw, Bruce L, et al.
Publicado: (2010) -
Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A
Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment
Strategies
por: Gower, Richard G, et al.
Publicado: (2011) -
Treatment of hereditary angioedema with plasma-derived C1 inhibitor
por: Prematta, Michael J, et al.
Publicado: (2008)